CN116287476A - New application of NPR in auxiliary evaluation of influenza virus infection severity - Google Patents
New application of NPR in auxiliary evaluation of influenza virus infection severity Download PDFInfo
- Publication number
- CN116287476A CN116287476A CN202310481355.6A CN202310481355A CN116287476A CN 116287476 A CN116287476 A CN 116287476A CN 202310481355 A CN202310481355 A CN 202310481355A CN 116287476 A CN116287476 A CN 116287476A
- Authority
- CN
- China
- Prior art keywords
- influenza
- npr
- influenza virus
- virus
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 47
- 230000009385 viral infection Effects 0.000 title claims abstract description 18
- 238000011156 evaluation Methods 0.000 title description 6
- 206010022000 influenza Diseases 0.000 claims abstract description 37
- 208000015181 infectious disease Diseases 0.000 claims abstract description 30
- 239000003550 marker Substances 0.000 claims abstract description 7
- 238000004393 prognosis Methods 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 10
- 241000712431 Influenza A virus Species 0.000 claims description 8
- 241000713196 Influenza B virus Species 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 238000011269 treatment regimen Methods 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- 230000010485 coping Effects 0.000 abstract description 2
- 238000011835 investigation Methods 0.000 abstract description 2
- 208000037798 influenza B Diseases 0.000 description 21
- 208000037797 influenza A Diseases 0.000 description 16
- 238000011282 treatment Methods 0.000 description 14
- 208000028399 Critical Illness Diseases 0.000 description 8
- 238000013211 curve analysis Methods 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 108010048233 Procalcitonin Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000010831 paired-sample T-test Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001500351 Influenzavirus A Species 0.000 description 2
- 241001500350 Influenzavirus B Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010832 independent-sample T-test Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000008383 multiple organ dysfunction Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940117432 influenza b virus antigen Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000013468 resource allocation Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to an application of NPR as an inflammation marker for assisting in detecting influenza virus severe infection in a sample. The NPR marker disclosed by the invention can be used for timely, rapidly, objectively and accurately evaluating the severity of the illness state of an influenza virus infected person, assisting medical staff in timely finding out a potential serious patient so as to distribute enough medical resources and attention, and can be used for evaluating the prognosis condition of the patient, and assisting in evaluating the epidemic situation of influenza and coping policies in research investigation of the serious influenza virus infection. The technology of the invention has great clinical application value for screening whether influenza virus infected patients are serious infection and potential serious patients.
Description
Technical Field
The invention belongs to the technical field of biological detection, and particularly relates to a novel application of NPR in auxiliary evaluation of influenza virus infection severity.
Background
Influenza is an acute respiratory viral infection, causing extremely high morbidity and mortality worldwide. Seasonal influenza refers to human disease caused by infection with seasonal influenza a or b viruses, with annual influenza pandemics of varying severity typically occurring in colder periods of the global temperate climate. Influenza is highly contagious and infections are characterized by sudden fever, coughing, coldness or sweating, myalgia and discomfort. Influenza is one of the most common causes of acute respiratory diseases and blindness in children, and community studies based on families and in different countries show that influenza virus infection and prevalence are highest among children, accounting for 2-11% of cases of encephalitis study in children. Influenza virus infection is usually self-limiting, but part of the population, especially the elderly, young children, pregnant women and those suffering from certain underlying diseases, is at high risk of complications such as pneumonia, sepsis, shock and multiple organ dysfunction, leading to the necessity of hospitalization or to nosocomial death. Certain risk factors such as age, obesity and other complications are associated with a higher likelihood of these infection complications in patients. Host factors (e.g., general health, genetics, age, immune function, and history of influenza virus immunity) have a very important impact on the severity of influenza virus infection, immunocompromised persons, immunocompromised elderly, pregnant women, and infants who have not acquired immunity from influenza virus infection or vaccination may develop severe infections, and in addition, influenza virus infection may exacerbate some chronic underlying diseases such as chronic obstructive pulmonary disease and coronary artery disease, which may make the case of viral infected persons more grooved. Nevertheless, it is notable that most influenza patients requiring intensive care, including adults and children, have no obvious risk factors or potential diseases. Currently, the clinical assessment of the severity of infection depends to a large extent on the clinical manifestations and symptoms of the patient, but the incidence of atypical patients with abnormal clinical manifestations is increasing. Thus, laboratory indicators are critical to help identify which patients are critically ill at an early stage of the clinic.
However, the current clinical common inflammation indexes include white blood cell differential count (WBC), C-Reactive protein (CRP), procalcitonin (PCT), interleukin 6 (il-6), and the like, which have certain clinical significance but lack specificity, sensitivity, clinical practicality, high cost, and the like, such as that only part of influenza virus infected patients have CRP increased and most of influenza patients have PCT normal, and both CRP and PCT have no relevance to mortality of influenza severe infected patients; compared with the infant with influenza A virus (Influenza Virus A, influ-A), the infant with influenza B virus (Influenza Virus B, influ-B) has no obvious rise of CRP level, no statistical difference of expression level between a severe infection group and a common infection group, and the like, so that laboratory indexes which are convenient, quick, practical and effective for screening severely infected influenza virus infected persons are lacking at present. In summary, determining a marker and providing a kit to rapidly evaluate the severity of the condition of an influenza virus infected patient at the time of admission, accurately distinguish between light and severe patients, help medical staff to find patients with severe infections in time, and have great significance in reducing overall mortality and optimizing medical resource allocation.
The ratio of neutrophil count to platelet count (NPR) is currently in clinical use, such as in aiding in the observation of prognosis in burn patients, and in judging prognosis in severe pneumonia patients, NPR is being developed for more clinical and research applications in view of the complexity of disease development and progression.
Disclosure of Invention
Based on this, it is an object of the present invention to provide new applications of NPR in medical detection, including aiding in the assessment of influenza virus infection severity.
The technical scheme for achieving the purpose comprises the following steps.
In a first aspect of the invention, there is provided the use of NPR as an inflammatory marker for detecting influenza virus infection in a sample for non-disease diagnostic methods.
In a second aspect of the invention, there is provided the use of a reagent for detecting NPR values in a sample in the preparation of a kit for assisting in the detection of influenza virus infection.
In a third aspect of the invention, there is provided the use of a reagent for detecting NPR values in a sample in the preparation of a kit for aiding in the assessment of a treatment regimen for influenza virus severe infection.
In a fourth aspect of the invention, there is provided the use of a reagent for detecting NPR values in a sample in the preparation of a kit for aiding in the assessment of prognosis of severe infection with influenza virus.
In a fifth aspect of the present invention, there is provided a method for assisted detection of influenza virus infection by a non-disease diagnostic method, characterized in that the NPR value in a sample to be detected is detected to obtain the NPR value.
In some of these embodiments, the influenza virus is an influenza a virus or an influenza b virus.
In some of these embodiments, the sample is a blood sample with a tester.
The NPR marker disclosed by the invention can be used for timely, rapidly, objectively and accurately evaluating the severity of the illness state of an influenza virus infected person, assisting medical staff in timely finding out a potential serious patient so as to distribute enough medical resources and attention, and can be used for evaluating the prognosis condition of the patient, and assisting in evaluating the epidemic situation of influenza and coping policies in research investigation of the serious influenza virus infection. The NPR marker has great clinical application value for screening whether influenza virus infected patients are severe infection and potential severe patients.
Compared with the traditional evaluation mode based on clinical manifestations and symptoms at present, the invention utilizes the data information of the neutrophil count and the platelet count ratio of the conventional detection of the blood of the influenza virus infected person, has higher AUC in the early rapid evaluation and screening of the severe influenza virus patients and stable result; the current evaluation method has lower accuracy due to higher and higher occurrence rate of subjective factors and atypical symptom patients, and cannot judge the severity of the illness state of the patients in time.
Compared with other clinical common inflammation markers, the NPR for rapidly judging the inflammation markers of the patients suffering from influenza virus infection has the advantages of easy acquisition of results, simple operation, rapid and accurate results, low cost, no need of clinical extra blood drawing, no increase of detection cost and result waiting time of the patients and the like, and is worthy of further research, popularization and application.
Drawings
FIG. 1NPR levels in individuals with different influenza infection.
The ROC curve analysis of FIG. 2 shows that NPR can better identify healthy control population and influenza virus infected population, wherein a is the ROC curve analysis chart of the NPR of Influ-A infected person, and B is the ROC curve analysis chart of the NPR of Influ-B infected person.
Figure 3 NPR of both the Influ-a and Influ-B critically infected groups (n=50 and n=54) were significantly higher than the normal infected group.
The ROC curve analysis of FIG. 4 shows that NPR can better identify the critically infected population and the non-critically infected population, wherein a is the ROC curve analysis graph of the NPR of Influ-A critically infected patients, and B is the ROC curve analysis graph of the NPR of Influ-B infected patients.
Figure 5. NPR values were significantly lower in influ-a critically ill infected subjects (n=8) after treatment than before treatment.
Figure 6. NPR values were significantly lower in influ-B critically ill infected subjects (n=6) after treatment than before treatment.
Detailed Description
The present invention will be described more fully hereinafter in order to facilitate an understanding of the present invention. This invention may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Experimental methods, in which specific conditions are not noted in the examples below, are generally carried out according to conventional conditions, for example, green and Sambrook-s.A.fourth edition, molecular cloning, A.laboratory Manual (Molecular Cloning: A Laboratory Manual), published in 2013, or according to the conditions recommended by the manufacturer. The various chemicals commonly used in the examples are commercially available.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and/or" as used herein includes any and all combinations of one or more of the associated listed items.
Influenza Virus A (Influ-A: influenza A).
Influenza Virus B, (Influ-B): influenza b.
Ratio of neutrophil count to platelet count: neutrophil-to-Platelet, NPR.
Youden index: about log index.
cut off value: a threshold value.
The present invention will be described in further detail with reference to specific examples.
Example 1
1. 2017.01.01-2021.09.30 were collected from patients who were diagnosed with influenza virus (type A or type B) infection and who were enrolled with other infections or who had been treated with antiviral therapy at a second people hospital in Guangdong province were excluded.
2. Diagnosis is completed by collecting throat swabs of patients for detecting influenza A virus and influenza B virus antigens, wherein the positive influenza A virus antigen is diagnosed as an influenza A (Influ-A) patient, and the positive influenza B virus antigen is diagnosed as an influenza B (Influ-B) patient.
3. All patients were routinely tested by collecting venous blood prior to treatment and recording the patient's neutrophil count and platelet count.
4. Collecting the group (each detection index is normal) of the healthy physical examination from the same time period to the hospital as a control group, and recording the neutrophil count and the platelet count of the control group.
5. The ratio NPR (Neu-tropil-to-Platelet, NPR) of neutrophil count and Platelet count was calculated for each healthy and virus-infected person.
6. The clinical data recorded for each patient included data for major clinical symptoms, diagnosis, chest X-ray examination, etc.
7. And combining the collected clinical data of the patients, and respectively dividing the influenza A patients and the influenza B patients into a common infection group and a severe infection group according to the diagnosis standard of severe diseases and critical diseases in the national institute of acute consultation of Chinese adult influenza diagnosis and treatment specifications.
Severe influenza cases: (1) For severe influenza high risk populations (e.g., populations over 65 years old, pregnant women, chronic underlying disease patient populations), the following are present: (1) the body temperature is more than or equal to 38.5 ℃ and continuously exceeds 3d; (2) obvious headache, dizziness, muscular soreness and fatigue; (3) poor appetite, obvious reduction of eating, vomiting and diarrhea; (4) obvious cough, expectoration and pharyngalgia; (5) influenza symptoms continue for 3 days without remission, exacerbation or reappearance after remission. (2) The emergency influenza case is one of the following, and is diagnosed as severe influenza: (1) the persistent high fever is more than 3 days, accompanied by severe cough, purulent phlegm, blood phlegm or chest pain; (2) rapid breathing rate, dyspnea, cyanosis of lips; (3) change of mind: reaction retardation, somnolence, agitation, convulsion, and the like; (4) severe vomiting, diarrhea, dehydration manifestation; (5) combining pneumonia; (6) the original basic disease is obviously aggravated.
(3) Diagnosis of critical influenza cases critical influenza is diagnosed when an emergency influenza case meets one of the following conditions: (1) progressive respiratory failure, requiring mechanical ventilation therapy; (2) the hypotension still continues after active liquid recovery, and the mean arterial pressure is maintained to be more than or equal to 65mmHg by using the vasoactive medicine; (3) acute necrotizing encephalopathy; (4) multiple organ dysfunction; (5) and (5) death cases.
Common influenza cases: mild respiratory symptoms and gastrointestinal symptoms such as fever, dry cough, aversion to cold, nasal obstruction, runny nose, headache, muscular soreness, vomiting, abdominal pain, diarrhea and the like appear.
8. Neutrophil counts and platelet counts were collected before and after treatment of critically ill hospitalized patients.
9. Patient and healthy control data were analyzed using statistical software SPSS 20.0, all data expressed as "mean ± standard deviation":
1) Assessing the ability of NPR to identify healthy control populations and influenza a or b virus infected individuals using a ROC curve;
2) The one-way anova was used to compare differences in NPR levels between healthy control, influenza a virus infected groups, influenza b virus infected groups;
3) The independent sample t-test was used to compare the difference in NPR levels between common influenza a virus infection and severe influenza a virus infection, common influenza b virus infection and severe influenza b virus infection;
4) Paired sample t-test was used to compare differences in NPR levels before and after treatment of severe influenza a virus patients and severe influenza b virus patients;
5) Assessing the ability of NPR to identify severe influenza a/b virus infected persons from common influenza a/b virus infected persons using ROC curves;
6) The cutoff value of NPR to identify influenza virus infected critically ill patients was determined by calculating the jouden index (Youden index).
1. In order to verify the clinical application value of NPR, partial clinically-confirmed Influ-A and Influ-B infection case data are collected, and after detection, the NPR values of the Influ-A group are obviously higher than those of the Influ-B group in 24h of admission of 2 groups of cases, and the NPR values of the Influ-A group are also obviously higher than those of the Influ-B group (see figure 1), and ROC curve graph analysis shows that the NPR has better effect of distinguishing healthy control groups from the Influ-A/B infection groups (see figure 2).
In fig. 1, the level of NPR in the population of different influenza infection cases is shown. NPR levels were significantly elevated in the Influ-a patient group (n=550) and the Influ-B patient group (n=541) compared to the healthy control group (n=62), and the Influ-a group was significantly elevated compared to the Influ-B group. Statistical analysis was done by one-way analysis of variance.
In fig. 2, analysis of ROC curves shows that NPR can better identify healthy control and influenza virus infected people. Wherein, in fig. 2 a, the area under the curve (The area under curve, AUC) is 0.704 (95% confidence interval: 0.648-0.760); in FIG. 2 b, under the curve
Area of
(AUC) is 0.662 (95% confidence interval: 0.605-0.720).
2. The infected group is divided into Influ-A/B common infection group and Influ-A/B severe infection group, and the NPR values of the severe infection group are obviously higher than those of the common infection group according to the analysis of the results, so that the NPR values are in positive correlation with the illness state of the infected person (see figure 3). ROC graph analysis showed that NPR had better discrimination of whether influenza virus infected persons were severe infection (see fig. 3), and the optimal cutoff value (critical value) of NPR discrimination between non-severe infection and severe infection patients was determined by calculating about log index, with the Influ-a group of 0.0281 (sensitivity at 80%, specificity at 53.2%) and the Influ-B group of 0.0288 (sensitivity at 46.3%, specificity at 79.6%).
In fig. 3, it is shown that NPR is significantly higher in both the Influ-a group (n=50) and Influ-B group of critically infected persons and (n=54) than in the normal infected persons. Statistical analysis was done by independent sample t-test.
In fig. 4, analysis of ROC curves shows that NPR can better identify critically infected and non-critically infected people. Wherein, in FIG. 4 a, the ROC curve analysis of NPR for Influ-A critically ill infected persons is shown, with an area under the curve (The area under curve, AUC) of 0.648 (95% confidence interval: 0.566-0.731); the ROC curve analysis of NPR for Influ-B critically ill infected persons is shown in FIG. 4B, with an area under the curve (AUC) of 0.648 (95% confidence interval: 0.568-0.729).
3. The values of NPR before and after treatment were collected for 8 cases of Influ-A severe patients and 6 cases of Influ-B severe patients, respectively, and comparison revealed that NPR levels were significantly decreased for both Influ-A and Influ-B infected patients after treatment (FIGS. 5 and 6), indicating that NPR could also be used to determine whether influenza virus severe patients were therapeutically effective.
In fig. 5, the NPR value of Influ-a critically ill infected persons (n=8) was significantly lower after treatment than before treatment. Statistical analysis was done by paired sample t-test.
In fig. 6, the NPR value of Influ-B severe infected persons (n=6) was significantly lower after treatment than before treatment. Statistical analysis was done by paired sample t-test.
The above results show that NPR can not only assist in detecting whether a patient sample is an influenza virus infection, but also can be used to assess the prognosis of influenza virus infection.
The above examples illustrate only a few embodiments of the invention, which are described in detail and are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Claims (10)
- The use of npr as an inflammatory marker for the assisted detection of influenza virus infection in a sample, said influenza virus being influenza a or influenza b, in a non-disease diagnostic method.
- 2. The use according to claim 1, wherein the sample is blood.
- 3. The application of a reagent for detecting NPR value in a sample in preparing a kit for assisting in detecting severe infection of influenza virus, wherein the influenza virus is influenza A virus or influenza B virus.
- 4. The use according to claim 3, wherein the sample is blood.
- 5. Use of a reagent for detecting NPR values in a sample for the preparation of a kit for aiding in the assessment of a treatment regimen for severe infection with an influenza virus, said influenza virus being influenza a or influenza b.
- 6. The use according to claim 5, wherein the sample is blood.
- 7. The use of a reagent for detecting NPR values in a sample for the preparation of a kit for aiding in the assessment of prognosis of severe infection with influenza virus, said influenza virus being influenza a or influenza b.
- 8. The use of claim 7, wherein the sample is blood.
- 9. A method for auxiliary detection of influenza virus severe infection by a non-disease diagnosis method is characterized in that NPR value in a sample to be detected is detected, and the influenza virus is influenza A virus or influenza B virus.
- 10. The method of claim 9, wherein the sample is blood.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310481355.6A CN116287476A (en) | 2023-04-28 | 2023-04-28 | New application of NPR in auxiliary evaluation of influenza virus infection severity |
| CN202311530690.7A CN117551731A (en) | 2023-04-28 | 2023-11-16 | New application of NPR in auxiliary evaluation of influenza virus infection severity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310481355.6A CN116287476A (en) | 2023-04-28 | 2023-04-28 | New application of NPR in auxiliary evaluation of influenza virus infection severity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116287476A true CN116287476A (en) | 2023-06-23 |
Family
ID=86788931
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310481355.6A Pending CN116287476A (en) | 2023-04-28 | 2023-04-28 | New application of NPR in auxiliary evaluation of influenza virus infection severity |
| CN202311530690.7A Pending CN117551731A (en) | 2023-04-28 | 2023-11-16 | New application of NPR in auxiliary evaluation of influenza virus infection severity |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311530690.7A Pending CN117551731A (en) | 2023-04-28 | 2023-11-16 | New application of NPR in auxiliary evaluation of influenza virus infection severity |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN116287476A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117551731A (en) * | 2023-04-28 | 2024-02-13 | 广东省第二人民医院（广东省卫生应急医院） | New application of NPR in auxiliary evaluation of influenza virus infection severity |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070239483A1 (en) * | 2006-01-09 | 2007-10-11 | Biophysical Corporation | Methods for individualized health assessment service |
| WO2008046528A1 (en) * | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Npr3 as a biomarker, therapeutic and diagnostic target |
| CN104093830A (en) * | 2011-04-15 | 2014-10-08 | 吉恩勒克斯公司 | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| CA3059362A1 (en) * | 2017-04-12 | 2018-10-18 | Vertex Pharmaceuticals Incorporated | Combination therapies for treating influenza virus infection |
| CN109001457A (en) * | 2018-09-13 | 2018-12-14 | 昆明医科大学第附属医院 | A kind of molecular marker combines the application in the risk assessment of patients with pneumonia |
| CN109593892A (en) * | 2019-01-28 | 2019-04-09 | 广州市华南农大生物药品有限公司 | A kind of universal primer group, kit and method expanding H5N6 subtype avian influenza virus full-length genome |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116287476A (en) * | 2023-04-28 | 2023-06-23 | 广东省第二人民医院（广东省卫生应急医院） | New application of NPR in auxiliary evaluation of influenza virus infection severity |
-
2023
- 2023-04-28 CN CN202310481355.6A patent/CN116287476A/en active Pending
- 2023-11-16 CN CN202311530690.7A patent/CN117551731A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070239483A1 (en) * | 2006-01-09 | 2007-10-11 | Biophysical Corporation | Methods for individualized health assessment service |
| WO2008046528A1 (en) * | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Npr3 as a biomarker, therapeutic and diagnostic target |
| CN104093830A (en) * | 2011-04-15 | 2014-10-08 | 吉恩勒克斯公司 | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| CA3059362A1 (en) * | 2017-04-12 | 2018-10-18 | Vertex Pharmaceuticals Incorporated | Combination therapies for treating influenza virus infection |
| CN109001457A (en) * | 2018-09-13 | 2018-12-14 | 昆明医科大学第附属医院 | A kind of molecular marker combines the application in the risk assessment of patients with pneumonia |
| CN109593892A (en) * | 2019-01-28 | 2019-04-09 | 广州市华南农大生物药品有限公司 | A kind of universal primer group, kit and method expanding H5N6 subtype avian influenza virus full-length genome |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117551731A (en) * | 2023-04-28 | 2024-02-13 | 广东省第二人民医院（广东省卫生应急医院） | New application of NPR in auxiliary evaluation of influenza virus infection severity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117551731A (en) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Testa et al. | Early recognition of the 2009 pandemic influenza A (H1N1) pneumonia by chest ultrasound | |
| Oduncu et al. | Comparison of qSOFA, SIRS, and NEWS scoring systems for diagnosis, mortality, and morbidity of sepsis in emergency department | |
| Flanders et al. | Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough | |
| Endo et al. | Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study | |
| Shields et al. | Serum eosinophilic cationic protein and blood eosinophil counts for the prediction of the presence of airways inflammation in children with wheezing | |
| Minderhoud et al. | Microbiological outcomes and antibiotic overuse in Emergency Department patients with suspected sepsis | |
| Schein et al. | Fatal aspergillosis complicating severe SARS-CoV-2 infection: A case report | |
| Liu et al. | SOFA score in relation to sepsis: clinical implications in diagnosis, treatment, and prognostic assessment | |
| CN117551731A (en) | New application of NPR in auxiliary evaluation of influenza virus infection severity | |
| Carpagnano et al. | Looking for airways periostin in severe asthma: could it be useful for clustering type 2 endotype? | |
| Genc Yavuz et al. | Clinical features of the 60 years and older patients infected with 2019 novel coronavirus: can we predict mortality earlier? | |
| Prasad et al. | Modified shock index as an indicator for prognosis among sepsis patients with and without comorbidities presenting to the emergency department | |
| CN109001457A (en) | A kind of molecular marker combines the application in the risk assessment of patients with pneumonia | |
| Huang et al. | Functional significance of cardiac rehabilitation-regulated expression of circulating MicroRNA-423-5p in hypertensive patients with heart failure with a moderately reduced ejection fraction | |
| Hur et al. | Role of plasma presepsin, procalcitonin and C-reactive protein levels in determining the severity and mortality of community-acquired pneumonia in the emergency department | |
| Goto et al. | The usefulness of a combination of age, body mass index, and blood urea nitrogen as prognostic factors in predicting oxygen requirements in patients with coronavirus disease 2019 | |
| Elhady et al. | Serum periostin level in children with bronchial asthma: a comparative study | |
| Chen et al. | Repeated pneumonia severity index measurement after admission increases its predictive value for mortality in severe community-acquired pneumonia | |
| Dong et al. | Diagnostic efficacy of lung ultrasound in cardiogenic pulmonary edema: a systematic review and meta-analysis. | |
| Alsayed et al. | Serum procalcitonin as a predicting value in severity and prognosis of CAP in sickle cell-patients | |
| Asim et al. | Assessment of Clinical Presentation and Prognosis of Patients with Acute-On-Chronic Liver Failure among Participants Admitted in the Intensive Care Units of Tertiary Care Hospitals in Pakistan | |
| CN113252910B (en) | Application of TIMP3 in anxiety and depression diagnosis | |
| Rao | Changes and significance of procalcitonin, C-reactive protein, peripheral leukocyte count and prealbumin in patients with severe pneumonia | |
| Ashour et al. | Serum and ascitic fluid high sensitive C reactive protein as prognostic marker in patients with spontaneous bacterial peritonitis | |
| Yeşiler et al. | Comparison of confirmed and probable COVID-19 patients in the intensive care unit during the normalization period |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230623 |